Laureate Pharma, Inc.
PRINCETON, N.J., and ATLANTA, Jan. 7 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company specializing in the development and GMP manufacture of monoclonal antibodies, fusion proteins and other therapeutic protein products, and Iconic Therapeutics, a company focused on the development of treatments for wet adult macular degeneration (wet AMD) and other ophthalmic diseases, today announced the completion of the manufacture of the first GMP lot of hI-con1 recombinant Fc-Factor VII fusion protein.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )
"We are very excited that Iconic Therapeutics now has material to test this new therapy for patients with macular degeneration and other diseases," said Robert J. Broeze, Ph. D., President & CEO of Laureate Pharma. "This is a testimonial to our strong partnership with Iconic and our expertise in working with fusion proteins." "Due to the unique properties of Iconic's hI-con1 fusion protein product, this project involved very close collaboration between our process-development team at Laureate and Iconic's product-development team," added Michiel E. Ultee, Ph.D., Vice President of Process Sciences.
"With clinical material now in hand, we have moved a giant step forward in our plans for hI-con1. We are excited about its prospects as a novel and powerful approach for the therapy of wet AMD," said Kirk Dornbush, President of Iconic Therapeutics. "We are very pleased with the strong working relationship that we established with Laureate Pharma."
hI-con1 is a recombinant protein intended to specifically attack and destroy pathological blood vessels (PBVs) with no effect on normal blood vessels. Since wet AMD is characterized by the invasion of PBVs into the eye, a drug that destroys these blood vessels could be very useful in treatment of this disease. In addition, hI-con1 is thought to act differently from other wet AMD treatments, which reduce the effects of pathological blood vessel invasion into the eye but do not appear to kill those blood vessels. In studies with mice and pigs, a single injection of hI-con1 into the eye resulted in dramatic reduction of pathological blood vessels.
About Laureate Pharma
Laureate Pharma is a full-service biopharmaceutical contract manufacturing company located in Princeton, NJ. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, QC testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Dan Leone, Vice President, Business Development at 609-919-3300, or [email protected] or visit www.laureatepharma.com.
About Iconic Therapeutics
Iconic Therapeutics, Inc., an Atlanta, Georgia-based development-stage biopharmaceutical company, is focused on the development of a recombinant immunoprotein known as human hI-con1, which is designed to destroy pathologic blood vessels without adverse effects on normal blood vessels. The first indication against which hI-con1 is being tested is wet adult macular degeneration (wet AMD). For more information, contact Kirk Dornbush, President, at 404-522-8577, or visit www.iconictherapeutics.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Mike Ultee
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=84358
Robert Broeze
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=84360
CONTACT: Dan Leone, Vice President, Business Development of Laureate
Pharma, +1-609-919-3300, [email protected]
Web site: http://www.laureatepharma.com/